TY - JOUR
T1 - Clinical proteomics
T2 - A need to define the field and to begin to set adequate standards
AU - Mischak, Harald
AU - Apweiler, Rolf
AU - Banks, Rosamonde E.
AU - Conaway, Mark
AU - Coon, Joshua
AU - Dominiczak, Anna
AU - Ehrich, Jochen H.H.
AU - Fliser, Danilo
AU - Girolami, Mark
AU - Hermjakob, Henning
AU - Hochstrasser, Denis
AU - Jankowski, Joachim
AU - Julian, Bruce A.
AU - Kolch, Walter
AU - Massy, Ziad A.
AU - Neusuess, Christian
AU - Novak, Jan
AU - Peter, Karlheinz
AU - Rossing, Kasper
AU - Schanstra, Joost
AU - Semmes, O. John
AU - Theodorescu, Dan
AU - Thongboonkerd, Visith
AU - Weissinger, Eva M.
AU - Van Eyk, Jennifer E.
AU - Yamamoto, Tadashi
PY - 2007/2
Y1 - 2007/2
N2 - The aim of this manuscript is to initiate a constructive discussion about the definition of clinical proteomics, study requirements, pitfalls and (potential) use. Furthermore, we hope to stimulate proposals for the optimal use of future opportunities and seek unification of the approaches in clinical proteomic studies. We have outlined our collective views about the basic principles that should be considered in clinical proteomic studies, including sample selection, choice of technology and appropriate quality control, and the need for collaborative interdisciplinary efforts involving clinicians and scientists. Furthermore, we propose guidelines for the critical aspects that should be included in published reports. Our hope is that, as a result of stimulating discussion, a consensus will be reached amongst the scientific community leading to guidelines for the studies, similar to those already published for mass spectrometric sequencing data. We contend that clinical proteomics is not just a collection of studies dealing with analysis of clinical samples. Rather, the essence of clinical proteomics should be to address clinically relevant questions and to improve the state-of-the-art, both in diagnosis and in therapy of diseases.
AB - The aim of this manuscript is to initiate a constructive discussion about the definition of clinical proteomics, study requirements, pitfalls and (potential) use. Furthermore, we hope to stimulate proposals for the optimal use of future opportunities and seek unification of the approaches in clinical proteomic studies. We have outlined our collective views about the basic principles that should be considered in clinical proteomic studies, including sample selection, choice of technology and appropriate quality control, and the need for collaborative interdisciplinary efforts involving clinicians and scientists. Furthermore, we propose guidelines for the critical aspects that should be included in published reports. Our hope is that, as a result of stimulating discussion, a consensus will be reached amongst the scientific community leading to guidelines for the studies, similar to those already published for mass spectrometric sequencing data. We contend that clinical proteomics is not just a collection of studies dealing with analysis of clinical samples. Rather, the essence of clinical proteomics should be to address clinically relevant questions and to improve the state-of-the-art, both in diagnosis and in therapy of diseases.
KW - Biomarker
KW - Clinical diagnostics
KW - Protein marker discovery
KW - Protein profiling
KW - Proteome analysis
UR - http://www.scopus.com/inward/record.url?scp=34047209848&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34047209848&partnerID=8YFLogxK
U2 - 10.1002/prca.200600771
DO - 10.1002/prca.200600771
M3 - Article
C2 - 21136664
AN - SCOPUS:34047209848
VL - 1
SP - 148
EP - 156
JO - Proteomics - Clinical Applications
JF - Proteomics - Clinical Applications
SN - 1862-8346
IS - 2
ER -